Ensure compliance with regulations

Urine Drug Testing

Advanced drug detection and screening for reliable results.

Reliable Testing
Reliable Testing

Accurate Urine Drug Testing (UDT) for prescription, recreational, and illicit drugs as well as alcohol is important for individuals, employers, and physicians. Exceltox uses highly-sensitive UDT screening and confirmatory testing technology to ensure reliable results.

Testing Process
Testing Process

The screening test uses an immunoassay to look for the parent drug and/or metabolite. If a confirmatory test is required it will be ran liquid chromatography/tandem-mass spectrometry (LC/MS/MS); the confirmatory test is very specific and is typically used when testing for the presence of a specific drug is needed. The methodology to obtain confirmation depends on the type of drug being tested.

Drugs & Alcohol

Benefits

UDT testing technology can detect:
Misuse of prescribed medication

Misuse of prescribed medication

Use of recreational or illicit drugs and non-prescribed medication

Use of recreational or illicit drugs and non-prescribed medication

Alcohol use or drug abuse

Alcohol use or drug abuse

Medication Monitoring

Benefits

Clinical Guidelines recommend physicians monitor prescribed medication to ensure safety and efficacy.

Confirm whether patient is adhering to treatment plan

Confirm whether patient is adhering to treatment plan

Detect early signs of medication misuse

Detect early signs of medication misuse

Identify discrepancies with patient self-reported medication use

Identify discrepancies with patient self-reported medication use

Increase dialogue with patient and physician

Increase dialogue with patient and physician

Increase the Standard of Care for your patient

Increase the Standard of Care for your patient

Ensure compliance with all state and federal regulations

Ensure compliance with all state and federal regulations

Test Menu

Benzodiazepines

Clonazapam
  • 7 aminoclonazepa
  • 7 aminoflunitrazepam
  • Alpha Hydroxyalprazolam
  • Alpha Hydroxymidazolam
  • Alpha Hydroxytriazolam
  • Desalkylflurazepam
  • Hydroxy Ethylflurazepam
Lorazepam
  • Lorazepam
Nordiazepam
  • Nordiazepam
Oxazepam
  • Oxazepam
Temazepam
  • Temazepam

Alcohol

Ethyl Alcohol
Ethyl Glucuronide (EtG)

Barbiturates

  • Amobarbital
  • Butalbital
  • Pentobarbital
  • Phenobarbital
  • Secobarbital

Stimulant

Methylphenidate
  • Methylphenidate
  • Ritalinic Acid

Muscle Relaxant

Carisprodal (Soma)
  • Carisprodal
  • Meprobamate

Semi-Synthetic Opiates

  • Oxycodone*
  • Oxymorphone
  • Buprenorphine
  • Norbuprenorphine

Sedative / Hypnotics

Zolpidem
  • Zolpidem
  • Zolp 4 Phenyl Carboxylic Acid

Nicotine

  • Cotinine

Opiates

Codeine
  • Dihydrocodeine
Hydrocodone
Hydromorphone
Morphine
  • Normeperidine

Synthetic Opiates

Propoxyphene
  • Propoxyphene
  • Norpropoxyphene
Meperidine
  • Meperidine
  • Normeperidine
Tramadol
  • Tramadol
  • Desmethyltramadol
Fentanyl
  • Fentanyl
  • Norfentanyl
Tapentadol
  • Tapentadol
  • Desmethyltapentadol
Methadone
  • EDDP
  • Methadone

Illicit Drugs

Cannabinoid
  • Carboxy THC
Alcohol
  • Ethyl Glucuronide (ETG)
  • Ethyl Sulfate (ETS)
Bath Salts
Cocaine
  • Benzoylecgonine
Phencyclidine (PCP) Ur Qual.
  • Phencyclidine (PCP)
Spice / K2
  • Spice / K2
Amphetamine
  • Methamphetamine**
  • MDA
  • MDMA
  • MDEA
Heroin
  • Acetylmorphine
MDMA / XTC
  • MDMA
  • MDEA

*Oral fluid testing is limited to these specific drugs.
**Methamphetamine screen is for oral fluids only.

References
  1. Mega, et al. JAMA. 2010;304:1821-30.
  2. Jannetto PJ, Bratanow NC. Pain management in the 21st century. Expert Opin Drug Metab Toxicol. 2011;7:745-752.
  3. De Gregori M, Allegri M, De Gregori S, et al. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab. 2010;11:276-282.
  4. Rollason V, Samer C, Piguet V, et al. Pharmacogenetics of analgesics. Pharmacogenomics. 2008;9:905-933.
  5. Wysowski D, et al. Bleeding Complications With Warfarin Use. Arch Intern Med 2007;167(13):1414-1419.
  6. Epstein et al. Warfarin Genotyping Reduces Hospitalization Rates. J Am Coll. Cardiol; 2010;55:2804-12.
  7. FDA, Black Box Warning, Coumadin, October 2006.